METHOTREXATE* IN PSORIASIS

Authors


  • *

    (Methotrexate-Amethopterin-4 amino-10 methyl-pteroylglutamic acid).

Abstract

SUMMARY. Seventeen patients with widespread psoriasis were treated with parenteral methotrexate over a period of 2–88 weeks. The injections were given every 1–4 weeks, in a dose of 12·5–37·5 mg.

The best results were obtained with a dose of 25 mg. of methotrexate once weekly. The improvement can be maintained only by continued treatment.

One of our patients suffered from psoriasis and systemic lupus erythematosus; both conditions were improved.

Apart from nausea and leukopenia no complications or side effects were noted. However, methotrexate is a potentially dangerous agent which should be administered only under careful hospital supervision.

In the light of our experience we feel that methotrexate in the treatment of psoriasis deserves further investigation.

Ancillary